SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Cardiovascular, renal and metabolic protection
Oral glucose-lowering medicines
SGLT2is
Sodium-glucose cotransporter-2 inhibitors
Standard of care
Type 2 diabetes mellitus
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
19
12
2023
accepted:
06
02
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
5
4
2024
Statut:
aheadofprint
Résumé
A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications, making their use highly applicable for organ protection and the maintenance of long-term health outcomes. SGLT2is have shown cost-effectiveness in T2DM management and economic savings over other glucose-lowering therapies due to reduced incidence of cardiovascular and renal events. National and international guidelines advocate SGLT2i use early in the T2DM management pathway, based upon a plethora of supporting data from large-scale cardiovascular outcome trials, renal outcomes trials and real-world studies. While most people with T2DM would benefit from CVRM protection through SGLT2i use, prescribing hesitancy remains, potentially due to confusion concerning their place in the complex therapeutic paradigm, variation in licensed indications or safety perceptions/misunderstandings associated with historical data that have since been superseded by robust clinical evidence and long-term pharmacovigilance reporting. This latest narrative review developed by the Improving Diabetes Steering Committee (IDSC) outlines the place of SGLT2is within current evidence-informed guidelines, examines their potential as the standard of care for the majority of newly diagnosed people with T2DM and sets into context the perceived risks and proven advantages of SGLT2is in terms of sustained health outcomes. The authors discuss the cost-effectiveness case for SGLT2is and provide user-friendly tools to support healthcare professionals in the correct application of these medicines in T2DM management. The previously published IDSC SGLT2i Prescribing Tool for T2DM Management has undergone updates and reformatting and is now available as a Decision Tool in an interactive pdf format as well as an abbreviated printable A4 poster/wall chart.
Identifiants
pubmed: 38578397
doi: 10.1007/s13300-024-01550-5
pii: 10.1007/s13300-024-01550-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757–73.
pubmed: 30039249
pmcid: 6167302
doi: 10.1007/s13300-018-0471-8
Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10:1595–622.
pubmed: 31290126
pmcid: 6778582
doi: 10.1007/s13300-019-0657-8
Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11:2757–74.
pubmed: 32996085
pmcid: 7524028
doi: 10.1007/s13300-020-00930-x
Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, et al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2022;13:847–72.
pubmed: 35307801
pmcid: 8934539
doi: 10.1007/s13300-022-01228-w
Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43:501–11.
pubmed: 28754263
doi: 10.1016/j.diabet.2017.06.003
Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina (Kaunas). 2023;59:182.
pubmed: 36676805
doi: 10.3390/medicina59010182
Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.
pubmed: 33097060
pmcid: 7585305
doi: 10.1186/s12933-020-01154-w
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline. NG28. 2022.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022, a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66.
pubmed: 36151309
pmcid: 9510507
doi: 10.1007/s00125-022-05787-2
IQVIA. Longitudinal prescription data: SGLT2 inhibitor prescribing data for England. 2023.
Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12: e230005.
pubmed: 37159343
pmcid: 10448577
doi: 10.1530/EC-23-0005
Evans M, Morgan AR, Bain SC, Davies S, Dashora U, Sinha S, et al. Defining the role of SGLT2 inhibitors in primary care: time to think differently. Diabetes Ther. 2022;13:889–911.
pubmed: 35349120
pmcid: 9076801
doi: 10.1007/s13300-022-01242-y
Alder A. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. UKPDS perspective, legacy effects and 44-year follow-up data [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https://www.easd.org/media-centre/#!resources/ukpds-perspective-legacy-effects-and-44-year-follow-up-data . Accessed 14 Mar 2024
Holman RR. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. Clinical outcomes at 44 years: do the legacy effects persist? [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https://www.easd.org/media-centre/#!resources/clinical-outcomes-at-44-years-do-the-legacy-effects-persist . Accessed 14 Mar 2024
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11:2465–76.
pubmed: 32975711
pmcid: 7547931
doi: 10.1007/s13300-020-00926-7
Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8: e012356.
pubmed: 31166153
pmcid: 6645638
doi: 10.1161/JAHA.119.012356
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
pubmed: 28605608
doi: 10.1056/NEJMoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
pubmed: 30415602
doi: 10.1056/NEJMoa1812389
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144:1284–94.
pubmed: 34459213
pmcid: 8522627
doi: 10.1161/CIRCULATIONAHA.121.056824
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction. Circulation. 2021;143:326–36.
pubmed: 33081531
doi: 10.1161/CIRCULATIONAHA.120.051783
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–75.
pubmed: 27539604
doi: 10.1681/ASN.2016030278
Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24:1072–83.
pubmed: 35166429
doi: 10.1111/dom.14671
Gonzalez Perez A, Vizcaya D, Sáez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care. 2023;11: e003072.
pubmed: 36596641
pmcid: 9814995
doi: 10.1136/bmjdrc-2022-003072
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.
pubmed: 35409011
pmcid: 8998569
doi: 10.3390/ijms23073651
Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310–30.
pubmed: 37202870
doi: 10.1111/dom.15111
Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1–10.
pubmed: 31743918
doi: 10.1159/000503919
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35.
pubmed: 32966714
doi: 10.1056/NEJMoa2004967
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.
pubmed: 30424892
doi: 10.1016/S0140-6736(18)32590-X
The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–27.
doi: 10.1056/NEJMoa2204233
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1-127.
Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022;16:223–44.
pubmed: 35183458
doi: 10.1016/j.pcd.2022.02.002
Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6: e009417.
pubmed: 26911584
pmcid: 4769433
doi: 10.1136/bmjopen-2015-009417
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–94.
pubmed: 27059700
doi: 10.1111/dom.12670
Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801.
doi: 10.1016/S0140-6736(22)02074-8
Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22:195.
pubmed: 37525273
pmcid: 10391899
doi: 10.1186/s12933-023-01937-x
Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271–82.
pubmed: 37154218
doi: 10.1080/17446651.2023.2210673
Chipayo-Gonzales D, Shabbir A, Vergara-Uzcategui C, Nombela-Franco L, Jimenez-Quevedo P, Gonzalo N, et al. Treatment with SGLT2 inhibitors in patients with diabetes mellitus and extensive coronary artery disease: mortality and cardiovascular outcomes. Diabetes Ther. 2023;14:1853–65.
pubmed: 37665429
pmcid: 10570247
doi: 10.1007/s13300-023-01454-w
Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Vokó Z, et al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105:302–12.
pubmed: 24956964
doi: 10.1016/j.diabres.2014.05.005
McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25:1830–8.
pubmed: 36864575
doi: 10.1111/dom.15040
Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66:642–56.
pubmed: 36404375
doi: 10.1007/s00125-022-05832-0
Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20:12.
pubmed: 32166504
doi: 10.1007/s11892-020-1292-5
Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, et al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9:3256.
pubmed: 30824788
pmcid: 6397228
doi: 10.1038/s41598-019-40191-8
Hodgson S, Morgan-Harrisskitt J, Hounkpatin H, Stuart B, Dambha-Miller H. Primary care service utilisation and outcomes in type 2 diabetes: a longitudinal cohort analysis. BMJ Open. 2022;12: e054654.
pubmed: 35105641
pmcid: 8808402
doi: 10.1136/bmjopen-2021-054654
Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145.
pubmed: 31345214
pmcid: 6659216
doi: 10.1186/s12916-019-1373-y
Zghebi SS, Steinke DT, Rutter MK, Ashcroft DM. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data. BMJ Open. 2020;10: e033866.
pubmed: 32611677
doi: 10.1136/bmjopen-2019-033866
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frigé C, De Cosmo S, et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Region Health Eur. 2023;31: 100666.
doi: 10.1016/j.lanepe.2023.100666
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–59.
pubmed: 28522450
pmcid: 5515629
doi: 10.1161/CIRCULATIONAHA.117.029190
Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh S-Y, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;20:159.
pubmed: 34332558
pmcid: 8325810
doi: 10.1186/s12933-021-01345-z
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27–35.
pubmed: 31862149
doi: 10.1016/S2213-8587(19)30384-5
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, et al. Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: the INTENSIFY study. J Clin Med. 2023;12:4248.
pubmed: 37445283
pmcid: 10342761
doi: 10.3390/jcm12134248
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
pubmed: 26378978
doi: 10.1056/NEJMoa1504720
Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021;8:1482–93.
pubmed: 33595905
pmcid: 8006652
doi: 10.1002/ehf2.13236
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
pubmed: 27299675
doi: 10.1056/NEJMoa1515920
Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–17.
pubmed: 31196815
doi: 10.1016/S2213-8587(19)30180-9
Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128:371–80.
pubmed: 27002421
doi: 10.1080/00325481.2016.1169894
Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
pubmed: 22238392
doi: 10.1210/jc.2011-2260
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–26.
pubmed: 26873905
doi: 10.1177/1479164115616901
Pratama K. Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: a systematic review. Acta Endocrinol (Bucharest). 2022;18:216–24.
doi: 10.4183/aeb.2022.216
Weingold R, Zinman B, Mattheus M, Ofstad AP, Steubl D, Wanner C, et al. Shifts in KDIGO CKD risk groups with empagliflozin: kidney-protection from SGLT2 inhibition across the spectrum of risk. J Diabetes Complic. 2023;37: 108628.
doi: 10.1016/j.jdiacomp.2023.108628
UK Kidney Association. UK Kidney Association clinical practice guideline: Sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease [Internet]. 2021 [cited 2023 Dec 19]. https://ukkidney.org/health-professionals/guidelines/ukka-clinical-practice-guideline-sodium-glucose-co-transporter-2 . Accessed 14 Mar 2024
A. Menarini Farmaceutica Internazionale SRL. Invokana 300 mg film-coated tablets. Summary of product characteristics [Internet]. 2021 [cited 2023 Dec 19]. https://www.medicines.org.uk/emc/product/11409 . Accessed 14 Mar 2024
Boehringer Ingelheim Limited. Jardiance 25 mg film-coated tablets. Summary of product characteristics [Internet]. 2023 [cited 2023 Dec 19]. https://www.medicines.org.uk/emc/product/7703/smpc . Accessed 14 Mar 2024
AstraZeneca UK Limited. Forxiga 10 mg film-coated tablets. Summary of product characteristics [Internet]. 2022 [cited 2023 Dec 19]. https://www.medicines.org.uk/emc/product/7607/smpc . Accessed 14 Mar 2024
Merck Sharp & Dohme (UK) Limited. Steglatro 15 mg film-coated tablets. Summary of product characteristics [Internet]. 2022 [cited 2023 Dec 19]. https://www.medicines.org.uk/emc/product/10099/smpc . Accessed 14 Mar 2024
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.
pubmed: 34447992
doi: 10.1093/eurheartj/ehab368
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
pubmed: 31497854
doi: 10.1093/eurheartj/ehz486
Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51:afac201.
pubmed: 36201329
pmcid: 9536439
doi: 10.1093/ageing/afac201
NHS Digital. National Diabetes Audit. Young people with Type 2 diabetes, 2019–20 [Internet]. 2021 [cited 2023 Jul 26]. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/young-people-with-type-2-diabetes-2019--20#top . Accessed 14 Mar 2024
TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385:416–26.
pmcid: 8697255
doi: 10.1056/NEJMoa2100165
ClinRisk Ltd. QRISK
ClinRisk Ltd. Welcome to the QRISK
National Institute for Health and Care Excellence. Putting NICE guidance in to Practice. Resource impact report: type 2 diabetes in adults: management (update) [Internet]. 2022 [cited 2023 Aug 4]. https://www.nice.org.uk/guidance/ng28/resources/resource-impact-report-type-2-diabetes-and-cardiovascular-risk-update-pdf-10958006557 . Accessed 14 Mar 2024
Butler J, Usman MS, Filippatos G, Ferreira JP, Böhm M, Brueckmann M, et al. Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction. JAMA Cardiol. 2023;8:640.
pubmed: 37223933
pmcid: 10209829
doi: 10.1001/jamacardio.2023.1090
Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9:254–64.
pubmed: 33549554
doi: 10.1016/j.jchf.2020.11.009
Peasah SK, Huang Y, Palli SR, Swart EC, Donato BM, Pimple P, et al. Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement. J Manag Care Spec Pharm. 2023;29:152–60.
pubmed: 36705285
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175:1392–400.
pubmed: 36191315
pmcid: 10155215
doi: 10.7326/M21-2941
National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. Technology appraisal guidance [TA390] [Internet]. 2016 [cited 2024 Jan 17]. https://www.nice.org.uk/guidance/ta390 . Accessed 14 Mar 2024
Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, et al. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complic. 2021;35: 107813.
doi: 10.1016/j.jdiacomp.2020.107813
Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) [Internet]. 2017 [cited 2023 Dec 19]. https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-increased-risk-of-lower-limb-amputation-mainly-toes#:~:text=Drug%20Safety%20Update-,SGLT2%20inhibitors%3A%20updated%20advice%20on%20increased%20risk%20of%20lower%2Dlimb,may%20be%20a%20class%20effect . Accessed 14 Mar 2024
Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) [Internet]. 2019 [cited 2023 Aug 7]. https://www.gov.uk/drug-safety-update/sglt2-inhibitors-reports-of-fournier-s-gangrene-necrotising-fasciitis-of-the-genitalia-or-perineum . Accessed 14 Mar 2024
Brown P. Need to know guide: SGLT2 inhibitor indications, doses and licences (updated 2023). Diabetes Prim Care. 2023;25:9–10.
Diggle J. Ketones and diabetes. Diabetes Prim Care. 2020;22:49–50.
Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020;2:218–21.
pubmed: 32734242
pmcid: 7380362
doi: 10.1016/j.xkme.2019.12.006
Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2023;47:1–4.
Brown P. How to use SGLT2 inhibitors safely and effectively. Diabetes Prim Care. 2023;25:113–5.
Vadi S, Lad V, Kapoor D. Perioperative implication of sodium-glucose cotransporter-2 inhibitor in a patient following major surgery. Indian J Crit Care Med. 2021;25:958–9.
pubmed: 34733046
pmcid: 8559749
doi: 10.5005/jp-journals-10071-23929
Kumar S, Bhavnani SP, Goyal P, Rich MW, Krishnaswami A. Preoperative cessation of SGLT2i [Internet]. American College of Cardiology. 2022 [cited 2023 Aug 14]. https://www.acc.org/Latest-in-Cardiology/Articles/2022/10/07/17/21/Preoperative-Cessation-of-SGLT2i . Accessed 14 Mar 2024
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. Ann Intern Med. 2019;171:248–56.
pubmed: 31357213
pmcid: 6989379
doi: 10.7326/M18-3136
Wilding J. SGLT2 inhibitors and urinary tract infections. Nat Rev Endocrinol. 2019;15:687–8.
pubmed: 31641244
doi: 10.1038/s41574-019-0275-6
Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023;25:2151–62.
pubmed: 37161691
doi: 10.1111/dom.15091
Dass AS, Immaculate G, Bhattacharyya A. Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience. Indian J Endocrinol Metab. 2019;23:165–6.
pubmed: 31016172
pmcid: 6446678
doi: 10.4103/ijem.IJEM_614_18
Yang JY, Wang T, Pate V, Buse JB, Stürmer T. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diabetes Res Care. 2020;8: e000985.
pubmed: 31958306
pmcid: 7039596
doi: 10.1136/bmjdrc-2019-000985
Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman CF, Zakia UB, et al. Fournier’s Gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022;14: e27773.
pubmed: 36106208
pmcid: 9450557
National Institute for Health and Care Excellence. Clinical Knowledge Summary—diabetes type 2 [Internet]. 2023 [cited 2023 Dec 19]. https://cks.nice.org.uk/topics/diabetes-type-2/ . Accessed 14 Mar 2024
Schaper NC, Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36: e3266.
pubmed: 32176447
doi: 10.1002/dmrr.3266
See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123–30.
pubmed: 34942623
doi: 10.1159/000520903
Scheen AJ. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies. Diabetes Epidemiol Manag. 2022;6: 100054.
doi: 10.1016/j.deman.2022.100054
Baker N. Diabetic foot care: a guide for non-specialists. J Diabetes Nurs. 2020;24:JDN144.
Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12:1227–47.
pubmed: 33830409
pmcid: 8099963
doi: 10.1007/s13300-021-01035-9
Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17:147916412095362.
doi: 10.1177/1479164120953625
Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142:1040–54.
pubmed: 32673497
pmcid: 7664959
doi: 10.1161/CIRCULATIONAHA.120.047077
van Ruiten CC, Hesp AC, van Raalte DH. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: update on recent mechanistic insights related to kidney physiology. Eur J Intern Med. 2022;100:13–20.
pubmed: 35414444
doi: 10.1016/j.ejim.2022.03.031
Lam D, Shaikh A. Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360. 2021;2:742–6.
pubmed: 35373039
pmcid: 8791327
doi: 10.34067/KID.0000412021
Sawaf H, Qaz M, Ismail J, Mehdi A. The renal effects of SGLT2 inhibitors. EMJ Nephrol. 2022. https://doi.org/10.33590/emjnephrol/22-00080 .
doi: 10.33590/emjnephrol/22-00080
Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7:125–37.
pubmed: 26758563
pmcid: 4801817
doi: 10.1007/s13300-015-0150-y
Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460–70.
pubmed: 35394821
doi: 10.1161/CIRCULATIONAHA.121.057736
Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.800490 . Accessed 14 Mar 2024
doi: 10.3389/fphar.2022.800490
pubmed: 36733375
pmcid: 9816472
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42:4891–901.
pubmed: 34423370
doi: 10.1093/eurheartj/ehab497
Zannad F, Rossignol P. Mineralocorticoid receptor antagonists and SGLT2 inhibitor therapy: the best of both worlds in HFrEF. JACC Heart Fail. 2021;9:265–7.
pubmed: 33714742
doi: 10.1016/j.jchf.2020.12.009
Yang S, Zhao L, Mi Y, He W. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab. 2022;24:2159–68.
pubmed: 35712807
doi: 10.1111/dom.14801
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154.
pubmed: 34315481
pmcid: 8317423
doi: 10.1186/s12933-021-01344-0
National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. Technology appraisal guidance. TA877 [Internet]. 2023 [cited 2023 Dec 19]. www.nice.org.uk/guidance/ta877 . Accessed 14 Mar 2024
Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24:135–41.
pubmed: 34558768
doi: 10.1111/dom.14559
Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, et al. The effects of canagliflozin on gout in type 2 diabetes: A post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1:e220–8.
pubmed: 38229378
doi: 10.1016/S2665-9913(19)30078-5
Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population-based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30:1391–5.
pubmed: 33881179
doi: 10.1002/pds.5252
Zhou J, Liu X, Chou OH-I, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023;62:1501–10.
pubmed: 36066415
doi: 10.1093/rheumatology/keac509
Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172:186–94.
pubmed: 31931526
pmcid: 7217750
doi: 10.7326/M19-2610
Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, et al. Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw Open. 2023;6: e2330885.
pubmed: 37624597
pmcid: 10457713
doi: 10.1001/jamanetworkopen.2023.30885
Down S. How to advise on sick day rules. Diabetes Prim Care. 2020;22:47–8.
Fernando K. Comparison of ADA/EASD and NICE Recommendations on the Pharmacological Management of Type 2 Diabetes In Adults [Internet]. Medscape. 2022 [cited 2023 Dec 19]. https://www.medscape.co.uk/viewarticle/primary-care-hacks-comparison-ada-easd-and-nice-2022a10024zc . Accessed 14 Mar 2024
Dashora U, Gregory R, Winocour P, Dhatariya K, Rowles S, Macklin A, et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). Clin Med (Lond). 2021;21:204–10.
pubmed: 34001571
doi: 10.7861/clinmed.2021-0045
Diabetes UK. Diabetes when you’re unwell [Internet]. [cited 2023 Dec 19]. https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/illness . Accessed 14 Mar 2024
International Diabetes Federation, Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical guidelines [Internet]. 2021 [cited 2023 Dec 19]. https://dar-safa-storage-bahrain.s3.me-south-1.amazonaws.com/IDF_Da_R_Practical_Guidelines_2021_web_166f7cbf4f.pdf . Accessed 14 Mar 2024
Hanif W, Patel V, Ali S, Karamat A, Hassanein M, Syed A, et al. The South Asian Health Foundation (UK) Guidelines for managing diabetes during Ramadan: 2020 Update [Internet]. 2020 [cited 2023 Dec 19]. https://static1.squarespace.com/static/5944e54ab3db2b94bb077ceb/t/5e847ebf2c6ec1680158c373/1585741505374/Ramadan+Guidelines+Update.pdf . Accessed 14 Mar 2024
Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B, et al. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2021;23:1085–93.
pubmed: 34031968
doi: 10.1002/ejhf.2220
Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183: 106396.
pubmed: 35970329
doi: 10.1016/j.phrs.2022.106396
Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang C-E, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146:1210–24.
pubmed: 36029465
pmcid: 9815819
doi: 10.1161/CIRCULATIONAHA.122.061754
Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023;22:16.
pubmed: 36694178
pmcid: 9875397
doi: 10.1186/s12933-023-01743-5
TREND Diabetes. Something you need to know: how to reduce your risk of genital fungal infection [Internet]. 2023 [cited 2023 Dec 19]. https://trenddiabetes.online/portfolio/something-you-need-to-know-how-to-reduce-you-risk-of-genital-fungal-infection/ . Accessed 14 Mar 2024
Diabetes UK. What is DKA (diabetic ketoacidosis)? [Internet]. [cited 2023 Dec 19]. https://www.diabetes.org.uk/guide-to-diabetes/complications/diabetic_ketoacidosis . Accessed 14 Mar 2024
TREND Diabetes. Type 2 diabetes and ketoacidosis [Internet]. [cited 2023 Aug 10]. https://trenddiabetes.online/wp-content/uploads/2022/03/A5_DKA_TREND.pdf . Accessed 14 Mar 2024
TREND Diabetes. What to do when you are ill [Internet]. 2022 [cited 2023 Dec 19]. https://trenddiabetes.online/wp-content/uploads/2020/03/A5_T2Illness_TREND_FINAL.pdf . Accessed 14 Mar 2024
TREND Diabetes. Looking after your feet when you have diabetes [Internet]. 2023 [cited 2023 Dec 19]. https://trenddiabetes.online/portfolio/looking-after-your-feet-when-you-have-diabetes/ . Accessed 14 Mar 2024
Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery [Internet]. 2022 [cited 2023 Dec 19]. https://cpoc.org.uk/sites/cpoc/files/documents/2022-12/CPOC-Diabetes-Guideline-Updated2022.pdf . Accessed 14 Mar 2024